Revenue
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Sarepta Therapeutics, Inc. (SRPT)
Price$18.22Cached quote
Net income
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.86B | $1.79B | $1.14B | $843.8M | $612.4M | $455.9M | $380.8M | $301.0M | $154.6M | $5.4M | $1.3M | $9.8M | $14.2M | $37.3M | $47.0M | $29.4M | — |
| Gross profit | $1.84B | $1.58B | $1.09B | $793.0M | — | — | — | — | — | $5.3M | — | — | — | — | — | — | — |
| Gross margin | 98.63% | 88.53% | 95.47% | 93.99% | — | — | — | — | — | 97.60% | — | — | — | — | — | — | — |
| Research & development | $1.52B | $804.5M | $877.4M | $877.1M | $771.2M | $722.3M | $560.9M | $401.8M | $166.7M | $188.3M | $146.4M | $94.2M | $72.9M | $52.4M | $66.9M | $36.0M | $24.4M |
| Operating expenses | $2.54B | $1.36B | $1.36B | $1.33B | — | — | $1.09B | $644.7M | $326.2M | $272.2M | $221.4M | $143.5M | $104.5M | $67.0M | — | — | — |
| Operating income | −$699.8M | $218.1M | −$267.8M | −$536.2M | −$459.7M | −$564.2M | −$705.6M | −$343.6M | −$171.6M | −$266.7M | −$220.2M | −$133.8M | −$90.3M | −$29.7M | −$35.9M | −$20.9M | −$15.5M |
| Operating margin | −37.54% | 12.20% | −23.39% | −63.55% | −75.07% | −123.76% | −185.27% | −114.15% | −111.03% | −4,920.31% | −17,572.55% | −1,371.21% | −634.95% | −79.57% | −76.46% | −71.16% | — |
| EBITDA | −$655.3M | $255.8M | −$223.4M | −$494.3M | −$421.7M | −$537.3M | −$681.1M | −$331.4M | −$163.5M | −$261.1M | −$214.9M | −$130.1M | −$89.0M | −$28.2M | −$34.6M | −$19.5M | −$14.1M |
| EBITDA margin | −35.15% | 14.31% | −19.52% | −58.59% | −68.86% | −117.85% | −178.84% | −110.08% | −105.80% | −4,816.81% | −17,153.79% | −1,333.39% | −625.97% | −75.49% | −73.69% | −66.18% | — |
| Net income | −$713.4M | $235.2M | −$536.0M | −$703.5M | −$418.8M | −$554.1M | −$715.1M | −$361.9M | −$50.7M | −$267.3M | −$220.0M | −$135.8M | −$112.0M | −$121.3M | −$2.3M | −$32.2M | −$25.2M |
| Net profit margin | −38.27% | 13.16% | −46.82% | −83.37% | −68.38% | −121.56% | −187.77% | −120.22% | −32.79% | −4,930.18% | −17,560.26% | −1,391.71% | −787.57% | −324.91% | −4.93% | −109.37% | — |
| Basic EPSper basic share | -$7.13 | $2.47 | -$5.80 | -$8.03 | -$5.15 | -$7.11 | -$9.71 | -$5.46 | -$0.86 | -$5.49 | -$5.20 | -$3.39 | -$3.31 | -$5.14 | -$0.12 | -$1.74 | -$1.62 |
| Diluted EPSper diluted share | -$7.13 | $2.34 | -$5.80 | -$8.03 | -$5.15 | -$7.11 | -$9.71 | -$5.46 | -$0.86 | -$5.49 | -$5.20 | -$3.39 | -$3.31 | -$5.14 | -$0.12 | -$1.74 | -$1.62 |
Owners
Reported shareholders
17.98%of listed shares
BlackRock, Inc.18.99M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
BlackRock, Inc. | 17.98%18.99M shares |
STATE STREET CORP | 8.44%8.92M shares |
VANGUARD PORTFOLIO MANAGEMENT LLC | 7.93%8.38M shares |
TWO SIGMA INVESTMENTS, LP | 4.35%4.6M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 4.35%4.59M shares |
FIRST TRUST ADVISORS LP | 4.13%4.37M shares |
AQR CAPITAL MANAGEMENT LLC | 4.10%4.33M shares |
Barry Richard | ≈3.06%3.23M shares |
GEODE CAPITAL MANAGEMENT, LLC | 2.62%2.77M shares |
Erste Asset Management GmbH | 2.43%2.57M shares |
MARSHALL WACE, LLP | 2.09%2.21M shares |
MORGAN STANLEY | 2.09%2.2M shares |
Aberdeen Group plc | 2.08%2.19M shares |
BANK OF AMERICA CORP /DE/ | 1.95%2.06M shares |
GOLDMAN SACHS GROUP INC | 1.93%2.04M shares |
UBS Group AG | 1.54%1.62M shares |
FEDERATED HERMES, INC. | 1.51%1.59M shares |
NORTHERN TRUST CORP | 1.15%1.21M shares |
MILLENNIUM MANAGEMENT LLC | 1.13%1.19M shares |
T. Rowe Price Investment Management, Inc. | 1.09%1.16M shares |
Percentages use 105.62M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Mar 12, 2026Form 4 | Mayo StephenDirector | SellCommon Stock | 7.2K | $17.02 | $123.2K | 1.8K |
| Dec 16, 2025Form 4 | Estepan Ian MichaelChief Operating Officer | SellCommon Stock | 13.2K | $22.31 | $294.2K | 193.3K |
| Mar 12, 2025Form 4 | Nicaise ClaudeDirector | SellCommon Stock | 2.5K | $99.64 | $248.2K | 27.8K |
| Dec 12, 2024Form 4 | Wigzell Hans Lennart RudolfDirector | SellCommon Stock | 10.5K | $124.84 | $1.31M | 22.8K |
| Dec 5, 2024Form 4 | Boor Kathryn JeanDirector | SellCommon Stock | 1.6K | $125.55 | $205.4K | 5.9K |
Community posts
Novartis’ DM1 trial misses its primary endpoint
Novartis’ ($NVS) del-desiran failed to show a statistically significant improvement on the primary endpoint in the Phase III HARBOR trial for myotonic dystrophy type 1. The company will continue analysing the data and discuss next steps wit ...
